CIK 0001035354
- Non-accelerated filer
- Smaller reporting company
Eloxx Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ELOX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 841368850
- Phone
- +1 781-577-5300
- Business address
- P.O. BOX 274, ARLINGTON, MA, 02476
- Former names
- Sevion Therapeutics, Inc., SENESCO TECHNOLOGIES INC, NAVA LEISURE USA INC
- 4 Open-market buy 10% owner bought 75,000 shares at $9.75 ($731,250)
- 4 Open-market buy 10% owner bought 350,000 shares at $9.75 ($3,412,500)
- 4 Open-market buy Director bought 350,000 shares at $9.75 ($3,412,500)
- 4 Open-market buy Director bought 300,000 shares at $9.75 ($2,925,000)
- 4 Open-market buy Director bought 350,000 shares at $9.75 ($3,412,500)
- 4 Open-market buy 10% owner bought 8,300 shares at an average $9.46 ($78,545)
- 4 Open-market buy 10% owner bought 4,500 shares at $9.64 ($43,380)
- 4 Open-market buy Director bought 2,000 shares at $9.49 ($18,980)
- 4 Open-market buy Chief Executive Officer bought 10,000 shares at $8.99 ($89,900)
- 4 Open-market buy Chief Financial Officer bought 4,500 shares at $8.56 ($38,520)
- 4 Open-market buy Director bought 12,600 shares at an average $7.76 ($97,830)
- 4 Open-market buy Director bought 12,600 shares at an average $7.76 ($97,830)
- 4 Open-market buy 10% owner bought 12,600 shares at an average $7.76 ($97,830)
- 4 Open-market buy Director bought 263 shares at $7.60 ($1,999)
- 3 Insider Initial Statement of Ownership
- 4/A Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
Page 9 of 29 · 574 filings